Literature DB >> 27033053

Alzheimer's Disease Genetic Risk Factor APOE-ε4 Also Affects Normal Brain Function.

Amanda M Di Battista, Nicolette M Heinsinger, G William Rebeck1.   

Abstract

APOE-ε4 is the strongest genetic risk factor for Alzheimer's disease (AD), and is associated with an increase in the levels of amyloid deposition and an early age of onset. Recent data demonstrate that AD pathological changes occur decades before clinical symptoms, raising questions about the precise onset of the disease. Now a convergence of approaches in mice and humans has demonstrated that APOE-ε4 affects normal brain function even very early in life in the absence of gross AD pathological changes. Normal mice expressing APOE4 have task-specific spatial learning deficits, as well as reduced NMDAR-dependent signaling and structural changes to presynaptic and postsynaptic compartments in neurons, particularly in hippocampal regions. Young humans possessing APOE-ε4 are more adept than APOE-ε4 negative individuals at some behavioral tasks, and functional magnetic resonance imaging has shown that inheritance of APOE-ε4 has specific effects on medial temporal brain activities. These findings suggest that inheritance of APOE-ε4 causes life long changes to the brain that may be related to the late risk of AD. Several possible mechanisms of how APOE-ε4 could affect brain neurochemistry, structure, and function are reviewed.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27033053      PMCID: PMC5839141          DOI: 10.2174/1567205013666160401115127

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  123 in total

1.  Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease.

Authors:  David A Wolk; Bradford C Dickerson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-17       Impact factor: 11.205

2.  Differential effects of the APOE genotype on brain function across the lifespan.

Authors:  N Filippini; K P Ebmeier; B J MacIntosh; A J Trachtenberg; G B Frisoni; G K Wilcock; C F Beckmann; S M Smith; P M Matthews; C E Mackay
Journal:  Neuroimage       Date:  2010-08-10       Impact factor: 6.556

3.  Altered medial temporal lobe responses during visuospatial encoding in healthy APOE*4 carriers.

Authors:  Paul R Borghesani; L Clark Johnson; Amy L Shelton; Elaine R Peskind; Elizabeth H Aylward; Gerard D Schellenberg; Monique M Cherrier
Journal:  Neurobiol Aging       Date:  2007-03-09       Impact factor: 4.673

4.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.

Authors:  Victor L Villemagne; Samantha Burnham; Pierrick Bourgeat; Belinda Brown; Kathryn A Ellis; Olivier Salvado; Cassandra Szoeke; S Lance Macaulay; Ralph Martins; Paul Maruff; David Ames; Christopher C Rowe; Colin L Masters
Journal:  Lancet Neurol       Date:  2013-03-08       Impact factor: 44.182

5.  APOE 4 polymorphism results in early cognitive deficits in an EAE model.

Authors:  Jiang-long Tu; Chong-bo Zhao; Timothy Vollmer; Stephen Coons; Hao-jie Lin; Stephen Marsh; David M Treiman; Jiong Shi
Journal:  Biochem Biophys Res Commun       Date:  2009-05-05       Impact factor: 3.575

6.  Increased plasma and lipoprotein lipid peroxidation in apo E-deficient mice.

Authors:  T Hayek; J Oiknine; J G Brook; M Aviram
Journal:  Biochem Biophys Res Commun       Date:  1994-06-30       Impact factor: 3.575

7.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.

Authors:  W J Strittmatter; A M Saunders; D Schmechel; M Pericak-Vance; J Enghild; G S Salvesen; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

8.  The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease.

Authors:  Radosveta P Koldamova; Iliya M Lefterov; Matthias Staufenbiel; Darren Wolfe; Shaohua Huang; Joseph C Glorioso; Michael Walter; Michael G Roth; John S Lazo
Journal:  J Biol Chem       Date:  2004-11-22       Impact factor: 5.157

9.  The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease.

Authors:  David R Riddell; Hua Zhou; Thomas A Comery; Evguenia Kouranova; C Frederick Lo; Helen K Warwick; Robert H Ring; Yolanda Kirksey; Suzan Aschmies; Jane Xu; Katie Kubek; Warren D Hirst; Catherine Gonzales; Yi Chen; Erin Murphy; Sarah Leonard; Dmytro Vasylyev; Aram Oganesian; Robert L Martone; Menelas N Pangalos; Peter H Reinhart; J Steve Jacobsen
Journal:  Mol Cell Neurosci       Date:  2007-01-25       Impact factor: 4.314

10.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium.

Authors:  L A Farrer; L A Cupples; J L Haines; B Hyman; W A Kukull; R Mayeux; R H Myers; M A Pericak-Vance; N Risch; C M van Duijn
Journal:  JAMA       Date:  1997 Oct 22-29       Impact factor: 56.272

View more
  32 in total

1.  Transcriptional signatures of brain aging and Alzheimer's disease: What are our rodent models telling us?

Authors:  Kendra E Hargis; Eric M Blalock
Journal:  Behav Brain Res       Date:  2016-05-04       Impact factor: 3.332

Review 2.  Peripheral versus central nervous system APOE in Alzheimer's disease: Interplay across the blood-brain barrier.

Authors:  Dustin Chernick; Stephanie Ortiz-Valle; Angela Jeong; Wenhui Qu; Ling Li
Journal:  Neurosci Lett       Date:  2019-06-07       Impact factor: 3.046

Review 3.  APOE in the normal brain.

Authors:  Sarah A Flowers; G William Rebeck
Journal:  Neurobiol Dis       Date:  2020-01-03       Impact factor: 5.996

Review 4.  The role of APOE on lipid homeostasis and inflammation in normal brains.

Authors:  G William Rebeck
Journal:  J Lipid Res       Date:  2017-03-02       Impact factor: 5.922

5.  Toward personalized cognitive diagnostics of at-genetic-risk Alzheimer's disease.

Authors:  Gillian Coughlan; Antoine Coutrot; Mizanur Khondoker; Anne-Marie Minihane; Hugo Spiers; Michael Hornberger
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-23       Impact factor: 11.205

6.  Dissociable effects of APOE-ε4 and β-amyloid pathology on visual working memory.

Authors:  Kirsty Lu; Jennifer M Nicholas; Yoni Pertzov; John Grogan; Masud Husain; Ivanna M Pavisic; Sarah-Naomi James; Thomas D Parker; Christopher A Lane; Ashvini Keshavan; Sarah E Keuss; Sarah M Buchanan; Heidi Murray-Smith; David M Cash; Ian B Malone; Carole H Sudre; William Coath; Andrew Wong; Susie M D Henley; Nick C Fox; Marcus Richards; Jonathan M Schott; Sebastian J Crutch
Journal:  Nat Aging       Date:  2021-10-07

Review 7.  Neurovascular Dysfunction in Diverse Communities With Health Disparities-Contributions to Dementia and Alzheimer's Disease.

Authors:  Napatsorn Saiyasit; Evan-Angelo R Butlig; Samantha D Chaney; Miranda K Traylor; Nanako A Hawley; Ryleigh B Randall; Hanna V Bobinger; Carl A Frizell; Franklin Trimm; Errol D Crook; Mike Lin; Benjamin D Hill; Joshua L Keller; Amy R Nelson
Journal:  Front Neurosci       Date:  2022-06-29       Impact factor: 5.152

8.  Vascular ApoE4 Impairs Behavior by Modulating Gliovascular Function.

Authors:  Yu Yamazaki; Chia-Chen Liu; Akari Yamazaki; Francis Shue; Yuka A Martens; Yuanxin Chen; Wenhui Qiao; Aishe Kurti; Hiroshi Oue; Yingxue Ren; Ying Li; Tomonori Aikawa; Yesesri Cherukuri; John D Fryer; Yan W Asmann; Betty Y S Kim; Takahisa Kanekiyo; Guojun Bu
Journal:  Neuron       Date:  2020-12-14       Impact factor: 17.173

9.  Expression and secretion of apoE isoforms in astrocytes and microglia during inflammation.

Authors:  Maria Fe Lanfranco; Jordy Sepulveda; Gregory Kopetsky; G William Rebeck
Journal:  Glia       Date:  2021-02-08       Impact factor: 8.073

10.  Development of a Human APOE Knock-in Mouse Model for Study of Cognitive Function After Cancer Chemotherapy.

Authors:  Andrew P Speidell; Tamar Demby; Yichien Lee; Olga Rodriguez; Christopher Albanese; Jeanne Mandelblatt; G William Rebeck
Journal:  Neurotox Res       Date:  2018-10-04       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.